Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
Hisaya Kawate, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to have favorable effects on bone and the lipid profile w...
Guardado en:
Autores principales: | Kawate H, Takayanagi R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a20acec5398f45c3a04962dcb0ec23be |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Eldecalcitol for the treatment of osteoporosis
por: Noguchi Y, et al.
Publicado: (2013) -
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
por: Luigi Gennari, et al.
Publicado: (2010) -
Selective estrogen receptor modulators: tissue specificity and clinical utility
por: Martinkovich S, et al.
Publicado: (2014) -
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Paula Rackoff
Publicado: (2009) -
Alendronate improves QOL of postmenopausal women with osteoporosis
por: Hisaya Kawate, et al.
Publicado: (2010)